PMID- 21146687
OWN - NLM
STAT- MEDLINE
DCOM- 20110208
LR  - 20181201
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 107
IP  - 1
DP  - 2011 Jan
TI  - Differential effect of telmisartan and amlodipine on monocyte chemoattractant 
      protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in 
      peripheral monocytes in patients with essential hypertension.
PG  - 59-63
LID - 10.1016/j.amjcard.2010.08.048 [doi]
AB  - Monocyte chemoattractant protein-1 (MCP-1) and peroxisome proliferator-activated 
      receptor-gamma (PPAR-gamma) play a significant role in monocyte activation, vascular 
      inflammation, and atherogenesis. Angiotensin receptor blockers and calcium 
      channel blockers are antihypertensive drugs with established efficacy and a 
      favorable safety profile. We investigated the effect of telmisartan--an 
      angiotensin receptor blocker with PPAR-gamma agonist activity--and amlodipine on the 
      activation state of peripheral blood monocytes with respect to MCP-1 and PPAR-gamma 
      gene expression in hypertensives. We recruited 31 previously untreated patients 
      with essential hypertension who were randomly assigned to receive treatment with 
      telmisartan (n = 16) or amlodipine (n = 15). Blood samples were taken before and 
      3 months after therapy initiation. Mononuclear cells were isolated and mRNAs of 
      MCP-1 and PPAR-gamma were estimated by real-time quantitative reverse 
      transcription-polymerase chain reaction each time. The 2 treatments decreased all 
      blood pressure components significantly (p <0.001). In contrast, in the 
      amlodipine group, MCP-1 gene expression was significantly downregulated after 
      treatment with telmisartan (from 21.4 +/- 20.5 to 8.1 +/- 6.5, p = 0.009), whereas 
      the amlodipine group did not show any significant change (12.5 +/- 8.5 vs 17.6 +/- 
      16.4, p = NS). In addition, PPAR-gamma mRNA levels showed a significant increase in 
      telmisartan-treated patients (from 20 +/- 18.5 to 42.6 +/- 36, p = 0.006) and no 
      significant alterations in the amlodipine group (from 29.6 +/- 42.5 to 24.2 +/- 27.7, 
      p = NS). In conclusion, treatment with telmisartan results in a significant 
      attenuation of MCP-1 gene expression and an increase of PPAR-gamma gene expression in 
      peripheral monocytes in patients with essential hypertension. Our findings may 
      provide new insights into the cardiovascular protection of telmisartan in 
      hypertensives.
CI  - Copyright (c) 2011. Published by Elsevier Inc.
FAU - Marketou, Maria E
AU  - Marketou ME
AD  - Cardiology Department, Heraklion University Hospital, Crete, Greece.
FAU - Kontaraki, Joanna E
AU  - Kontaraki JE
FAU - Tsakountakis, Nikolaos A
AU  - Tsakountakis NA
FAU - Zacharis, Evangelos A
AU  - Zacharis EA
FAU - Kochiadakis, George E
AU  - Kochiadakis GE
FAU - Arfanakis, Dimitris A
AU  - Arfanakis DA
FAU - Parthenakis, Frangiskos
AU  - Parthenakis F
FAU - Chlouverakis, Gregory
AU  - Chlouverakis G
FAU - Vardas, Panos E
AU  - Vardas PE
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Benzoates)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (PPAR gamma)
RN  - 1J444QC288 (Amlodipine)
RN  - U5SYW473RQ (Telmisartan)
SB  - IM
MH  - Amlodipine/*pharmacology/therapeutic use
MH  - Antihypertensive Agents/*pharmacology/therapeutic use
MH  - Benzimidazoles/*pharmacology/therapeutic use
MH  - Benzoates/*pharmacology/therapeutic use
MH  - Chemokine CCL2/drug effects/*genetics
MH  - Female
MH  - Gene Expression/drug effects
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Monocytes/*drug effects
MH  - PPAR gamma/*genetics
MH  - Severity of Illness Index
MH  - Telmisartan
EDAT- 2010/12/15 06:00
MHDA- 2011/02/09 06:00
CRDT- 2010/12/15 06:00
PHST- 2010/06/10 00:00 [received]
PHST- 2010/08/24 00:00 [revised]
PHST- 2010/08/24 00:00 [accepted]
PHST- 2010/12/15 06:00 [entrez]
PHST- 2010/12/15 06:00 [pubmed]
PHST- 2011/02/09 06:00 [medline]
AID - S0002-9149(10)01731-5 [pii]
AID - 10.1016/j.amjcard.2010.08.048 [doi]
PST - ppublish
SO  - Am J Cardiol. 2011 Jan;107(1):59-63. doi: 10.1016/j.amjcard.2010.08.048.